As Allergan enters a key phase for late-stage products crucial to its turnaround, it’s poached a Pfizer veteran to help bring its plans to fruition.
The Dublin drugmaker has brought on Charles Hugh-Jones, the chief medical officer at Pfizer’s oncology unit, to serve as its new senior vice president and chief medical officer, it said Monday. He’ll start his new gig this month and report to Allergan R&D head David Nicholson.
“Allergan is in a position to launch a number of important new products over the next couple of years. Charles will play a critical role in supporting the safe, effective and proper use of these innovative treatments among patients and their physicians,” Nicholson said in a statement.
The move cuts short a Pfizer stint that began just 16 months ago. Before that, Hugh-Jones spent six years at Sanofi in various roles including North American chief medical officer and head of medical affairs for U.S. oncology.
Hugh-Jones won’t be putting that oncology expertise to use at his new employer, though. Allergan focuses on other therapeutic areas, including aesthetics and central nervous system conditions, and some of its most closely watched pipeline candidates include two migraine therapeutics and a depression treatment, rapastinel.
Hugh-Jones’ role will be a crucial one, as it’s high stakes for Allergan’s pipeline right now. The drugmaker’s shares have been suffering for months, and some analysts believe it’s up to the company’s pipeline to turn things around.
And if they can’t? Allergan’s R&D ranks could see some additional personnel changes down the line, Credit Suisse analyst Vamil Divan predicted earlier this year. “Continued challenges with the pipeline could lead to further pressure to change the company’s R&D leadership,” he wrote in a note to clients.
Meanwhile, Hugh-Jones is the second big exec loss for Pfizer Oncology this year. In January, the New York pharma giant saw its global president and general manager of the unit, Liz Barrett, depart to take up the reins as CEO of Novartis Oncology.
By Carly Helfand
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
